Year: 2020

STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will participate in a Fireside Chat at the 3rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Wednesday, December 2, 2020 at 12:35 p.m. ET.A video webcast will be available on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying...

Martela Oyj: Managers’ transactionsPerson subject to the notification requirementName: Vepsäläinen, AnniPosition: Member of the BoardIssuer: Martela OyjLEI: 743700M4EIEVD61PNN55Notification type: INITIAL NOTIFICATIONReference number: 743700M4EIEVD61PNN55_20201124082826_2Transaction date: 2020-11-19Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009900385Nature of the transaction: ACQUISITIONTransaction details(1): Volume: 2,000 Unit price: 2.55000 EURAggregated transactions(1): Volume: 2,000 Volume weighted average price: 2.55000 EURMartela PLCKalle LehtonenCFOtel +358 400 539 968Distribution:Nasdaq Helsinkiwww.martela.comOur strategic direction is defined by our mission “Better working” and our vision “People-centric workplaces”. Martela provides people centric workplaces where the users and their wellbeing are...

Martela Oyj: Johdon liiketoimetIlmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700M4EIEVD61PNN55_20201124082826_2Liiketoimen päivämäärä: 2020-11-19Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Instrumenttityyppi: OSAKEISIN: FI0009900385Liiketoimen luonne: HANKINTALiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 2 000 Yksikköhinta: 2,55000 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 2 000 Keskihinta: 2,55000 EURMartela OyjKalle LehtonenTalousjohtajapuh 0400 539 968Jakelu:Nasdaq Helsinkiwww.martela.fiMissiomme ”better working” ja visiomme ”people centric workplaces” määrittelevät strategisen suuntamme. Martela toimittaa käyttäjälähtöisiä työympäristöjä, joissa käyttäjät ja heidän hyvinvointi ovat keskiössä. Keskitymme  Pohjoismaihin, sillä yhteisen avoimen työkulttuuritaustamme ja tarpeidemme myötä Pohjoismaat ovat hybridien työympäristöjen...

Please find attached the Q3 2020 presentation to be held in the digital meeting today, 24 November 2020, at 12:00 UK time (13:00pm CET / 07:00 EST).To join the digital meeting, please click this link or copy and paste the following address into your browser: https://bit.ly/AWDR-Q3-2020Aberdeen, 24 November 2020For further information please contact:Jens Berge, CEOPhone: +44 1224 737900Cathrine Haavind, IR ManagerPhone: +47 93 42 84 64Email: ch@awilcodrilling.comThis information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. AttachmentAWDR Q3 2020 pres

Nørresundby, 24 November 2020Announcement no. 39/2020 

Nørresundby, den 24. november 2020Selskabsmeddelelse nr. 39/2020Årsrapport 2019/20(perioden 01.10.2019 – 30.09.2020)Regnskabsåret 2019/20 udviklede sig ganske anderledes end forventet. COVID-19 pandemien, og de modforanstaltninger, som er iværksat i hele verden mod pandemien, har resulteret i en global økonomisk usikkerhed, som også har påvirket RTX’s markeder. RTX’s forretningsmodel er dog fortsat stærk, og med en tæt omkostningsstyring har RTX formået at slutte året med en indtjening indenfor de oprindelige forventninger på trods af en omsætning, som blev lavere end oprindeligt forventet.HOVEDPUNKTER I ÅRSRAPPORTEN FOR 2019/20RTX indfriede de forventninger til indtjeningen, som blev annonceret i starten af året på trods af, at omsætningen blev lavere end oprindeligt forventet på grund af COVID-19 og den efterfølgende globale økonomiske...

Reykjavik Energy (OR; Orkuveita Reykjavikur) will conduct a closed auction of inflation linked green bonds in the series OR020934 GB and OR180255 GB on December 1st, 2020.OR020934 GB pays a fixed real-interest rate, has a semiannual annuity amortization schedule and a final maturity on September 2nd 2034.OR0180255 GB pays a fixed real-interest rate, has a semiannual annuity amortization schedule and a final maturity on February 18th 2055.Previously issued bonds in the series amount to a nominal value of ISK 7,145m in OR020934 GB and ISK 21,981m in OR180255 GB.The bond offering confirms with approved financing in the form of loans, bonds or bills of Reykjavík Energy for the year 2020.Fossar Markets will manage the auction on behalf of OR and will handle investor relations.Further information:Ingvar StefánssonCFO, Reykjavik Energy+354 516-6100ingvar.stefansson@or.isMatei...

Þriðjudaginn 1. desember 2020 verða boðin til sölu í lokuðu útboði skuldabréf í grænum skuldabréfaflokkum Orkuveitu Reykjavíkur, OR020934 GB og OR180255 GB.OR020934 GB ber fasta verðtryggða vexti og greiðir jafnar greiðslur á sex mánaða fresti með lokagjalddaga 2.september 2034.OR0180255 GB ber fasta verðtryggða vexti og greiðir jafnar greiðslur á sex mánaða fresti með lokagjalddaga 18. febrúar 2055.Áður hafa verið gefin út bréf í flokkunum að nafnvirði 7.145 m.kr. í OR020934 GB og að nafnvirði 21.981 m.kr. í OR180255 GB.Útgáfa skuldabréfaflokkanna er í samræmi við áður samþykkta lántökuheimild Orkuveitu Reykjavíkur fyrir árið 2020.Fossar markaðir hafa umsjón með útgáfu og sölu skuldabréfanna.Nánari upplýsingar:Ingvar StefánssonFramkvæmdastjóri Fjármála ORSími: 516-6100Netfang: ingvar.stefansson@or.isMatei ManolescuMarkaðir, Fossar markaðirSími:...

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin’s president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) taking place from December 1 – December 3, 2020. Mr. Thero’s presentation is scheduled to take place on Wednesday, December 2, 2020 at 10:00 am Eastern time.A live audio webcast of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.About AmarinAmarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA®...

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year.This release has been authorised by the directors of Immuron Limited.About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases....